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A B S T R A C T

The interferons (IFNs) are glycoproteins with strong antiviral activities that represent one of the ﬁrst
lines of host defense against invading pathogens. These proteins are classiﬁed into three groups, Type I, II
and III IFNs, based on the structure of their receptors on the cell surface. Due to their ability to modulate
immune responses, they have become attractive therapeutic options to control chronic virus infections.
In combination with other drugs, Type I IFNs are considered as ‘‘standard of care’’ in suppressing
Hepatitis C (HCV) and Hepatitis B (HBV) infections, while Type III IFN has generated encouraging results
as a treatment for HCV infection in phase III clinical trials. However, though effective, using IFNs as a
treatment is not without the need for caution. IFNs are such powerful cytokines that affect a wide array of
cell types; as a result, patients usually experience unpleasant symptoms, with a percentage of patients
suffering system wide effects. Thus, constant monitoring is required for patients treated with IFN in
order to reach the treatment goals of suppressing virus infection and maintaining quality of life.
ß 2014 Elsevier Ltd. All rights reserved.

1. Introduction
The interferons (IFNs) were ﬁrst described in 1957 as a
heterogeneous class of soluble glycoproteins with strong antiviral
activities. The induction of their expression occurs in response to
viruses or bacteria infection. IFNs are classiﬁed into three types of
IFNs, Type I, II and III, based on the structure of their receptors on
the cell membrane surface. Due to their ability to modulate
immune responses, they have been considered as a treatment
option for several cancers and autoimmune diseases (Table 1).
With the development of recombinant IFNs, IFNs becomes even
more attractive therapeutic options since their supply was no
longer limited. As a consequence of the clinical failures in
controlling chronic virus infection using only antiviral drugs,
due to the generation of drug resistant strains, treatment options
like IFNs that target the host immune response rather than speciﬁc
viral proteins, become an important component of the treatment
regimen. Indeed, in recent years, Type I IFNs have been part of the
standard treatment for HCV and HBV infections and the appearance of IFN-resistant viral subpopulations has not been observed.
In addition, there is a growing interest in testing the antiviral
efﬁcacy of the new member of IFN, Type III IFN, in HCV infection
based on the fact that the Type III IFN receptor is more restricted in
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its expression and is present on hepatocytes. In this review, we will
discuss the biology and the antiviral activities of the IFNs, as well as
their use in antiviral therapy in human diseases.
2. Type I interferons: interferon-alpha/beta (IFN-a/b)
2.1. Type I interferons signaling pathway
Type I IFNs belong to the class II family of a-helical cytokines,
including, IFN-g, IFN-ls (Type III IFNs), IL-10 and several IL-10
homologs (IL-19, IL-20, IL-22, IL-24 and IL-26). Type I IFNs can be
produced by all nucleated cells in response to viral or microbial
infections. In humans, the Type I IFN family is composed of 12 IFNa subtypes encoded by 14 genes, IFN-b encoded by a single IFNB
gene, and IFN-e, IFN-k and IFN-v [1]. In this review, we will focus
on the two well-characterized Type I IFNs, IFN-a and IFN-b. All
Type I IFNs signal by binding to the same heterodimeric receptor
IFNa/b receptor (IFNAR). IFNAR is expressed by nearly all cell
types and consists of IFNAR1 and IFNAR2 subunits that are
associated with tyrosine kinase 2 (TYK2) and Janus kinase 1(JAK1)
respectively. Binding to IFNAR results in activation of TYK2 and
JAK1 that phosphorylate the tyrosine residues in the IFNAR
cytoplasmic domains, thus creating docking sites for signal
transducers and activators of transcription (STATs), (STAT1, STAT2
and STAT3 in most cell types), which are then targeted by JAK for
phosphorylation. Phosphorylated STATs (pSTATs) form either
homodimers or heterodimers and translocate into the nucleus.
The pSTAT1 homodimer binds to gamma-activated sequence (GAS,
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Table 1
Current FDA approved IFN therapeutic agents.
Brand name

Generic name

Manufacturers

Descriptions

Type I IFNs
Alferon N
Infergen
Pegasys

IFN-an3
IFN-acon1
Peg-IFN-a2a

Hemispherx
Intermune Pharms
Roche

Referon A

IFN-a2a

Roche

Intron A

IFN-a2b

Schering

PegIntron/Sylaton

Peg-IFN-a2b

Schering

Rebif
Avonex
Betaseron
Extavia

IFN-b1a
IFN-b1a
IFN-b1b
IFN-b1b

Merk Serono
Biogen Idec
Bayer
Novartis

Approved for the treatment of genital and perianal warts caused by human papillomavirus (HPV)
Approved for the treatment of HCV
Approved for the treatment of HBV adult patients negative, HCV patients 5 years of age and older
not previously treated with IFN-a, and HCV/HIV coinfected patients.
Approved to treat hairy cell leukemia, AIDS-related Kaposi’s sarcoma, and chronic myelogenous
leukemia.
Approved for the treatment of HBV patients 1 year of age or older and HCV patient 18 years of age or
older
Approved for the treatment of HCV patients 18 years of age or older who previously untreated with
IFN-a
Approved for the treatment of multiple sclerosis
Approved for the treatment of multiple sclerosis
Approved for the treatment of multiple sclerosis
Approved for the treatment of multiple sclerosis

Type II IFN
Actimmune

IFN-g1b

Vidara Therapeutics

Approved for the treatment of chronic granulomatous disease, and severe, malignant osteopetrosis

TTCNNNGAA) in the promoter region of interferon stimulated
genes (ISGs) and initiates the transcription of these target genes,
while the homodimer formed by pSTAT3 activates the transcription of genes containing the enhancer sequence STAT3-binding
element.
Phosphorylated STAT1 and STAT2 form a heterodimer that
leads to the recruitment of IRF9 and the formation of the IFNstimulated gene factor 3 (ISGF3) complex. This complex then
transfers to the nucleus and binds to IFN-stimulated response
elements (ISREs) in the promoter region of IFN responsive genes
(ISGs) to initiate transcription of genes that are pivotal for Type I
antiviral activities (Fig. 1) [2,3]. In addition to STAT1, STAT2 and
STAT3, it has been shown that Type I IFN can also activate STAT4,
STAT5 and STAT6 in certain cell types [4]. Activation of JAK can also
induce several alternative signaling pathways, including the PI3K,
NF-kB and MAPK pathways, which further ampliﬁes Type I IFN
signaling strength and magnitude.

2.2. Antiviral activity
Type I IFN induces an array of proteins that interfere with virus
replication in order to restrict and limit viral spread from cell to cell
[5,6]. 20 -50 -oligoadenylate synthetase (OAS) is an enzyme induced
by Type I IFN that activates latent nuclease RNaseL which then
mediates viral RNA degradation. Another induced enzyme,
protein kinase RNA-activated (PKR), a member of the eukaryotic
initiation factor 2a family, prevents the recycling of guanidine
diphosphate which in turns blocks viral RNA translation. Other
notable antiviral proteins induced by Type I IFN are myxovirus
resistance (Mx) GTPases which restrict viral nucleocapsid localization, interferon stimulated gene 15 (ISG15) and tripartite motif
(TRIM) protein which interfere with the release of viral particles, as
well as APOBEC3, a protein that induces hypermutation of viral
DNA. To conﬁne and localize the infection, Type I IFNs also can
activate the apoptosis mechanism to eliminate virus infected cells

Fig. 1. Interferon canonical signaling pathways. Types I, II and III IFNs bind to their speciﬁc receptors on the cell membrane and trigger JAK-STAT signaling pathway. While
Types I and III can phosphorylate both STAT1 and STAT2 to form ISGF3 and GAF that binds to ISRE and GAS respectively in the promoter region of responding genes, Type II IFN
can only phosphorylate STAT1 and induce expression of genes with GAS in the promoter region.
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by up regulating Fas ligand (FasL), PDL-1 and TRAIL. In addition to
activating the antiviral mechanism in the infected cells, Type I IFN
can also limit virus infection by modulating both innate and
adaptive immunity. Type I IFNs directly activate NK cells to
enhance their cytotoxicity to eliminate infected cells and conﬁne
the infection. However, complete elimination of intracellular
infection by pathogens requires activation of the adaptive immune
response and the Type I IFNs have an active role in this activation
process. Type I IFNs promote the maturation of dendritic cells
(DCs) that facilitate CD4+ T cell differentiation into either Th1 or
Th2 cells [5,6]. Studies have shown that Type I IFN experienced
APCs are capable of cross-presentation and stimulate naı̈ve CD8+ T
cells, resulting in clonal expansion and proliferation. These Type I
IFN experienced DCs have increased expression of chemokines that
recruit NK, T and B cells to the site of infection, and IL-15 which is
important in NK and CD8+ memory cell maintenance. All these cell
intrinsic and extrinsic effects of Type I IFNs prepare the host
immune system to mount an effective response against intracellular pathogens.
2.3. IFN-a as a therapeutic agent for HCV infections
Chronic infection with HCV is a major health problem with
approximately 180 million people infected worldwide. While more
than 80% of HCV chronic infection is asymptomatic, 5–30% of
infected patients develop cirrhosis and sometimes advance to
severe liver disease including variceal hemorrhage and hepatocelluar carcinoma (HCC). Currently, there are several drugs
targeting virus replication that have been FDA approved for
clinical use. However, due to the high incidence of drug resistant
HCV strains, the consequences of a promiscuous RNA polymerase,
the treatment with the antiviral drugs alone has been less than
effective although new antiviral drugs show more promise [7].
With its extensive antiviral activity, recombinant IFN-a was ﬁrst
used in HCV treatment in 1986. However, because of the rapid
absorption, short half-life and rapid elimination by the kidney, the
result was less than desirable, even with the addition of the
nucleoside analogue ribavirin. To allow for slower absorption and
maintenance of sustained and stable blood levels, pegylated IFN,
synthesized by attaching a polyethylene glycol (PEG) moiety, was
introduced into the clinic in 2001 [8,9]. The change was less
traumatic for the patients as it only required a weekly injection of
Type I IFN, instead of injection three times a week. Currently, the
accepted standard treatment for chronic HCV infection is weekly
subcutaneous pegylated IFN-a (PEG-IFN-a) injection with oral
daily ribavirin. The treatment goal is to achieve sustained virologic
response (SVR) with undetectable HCV RNA by the end of the
treatment period. PEG-IFN-a/ribavirin treatment in HCV infection
produces highly desirable results. Approximately 80% of patients
achieve SVR at the end of treatment period. Currently, there are
two PEG-IFN-as available in clinical use, IFN-a2a and IFN-a2b, for
HCV treatment. While the IFN-a2 subtype has a lower binding
afﬁnity to its receptor that is associated with a lower antiproliferative potency, there is no difference in the antiviral effect
compared to other subtypes [10]. However, comparing IFN-a2a
and IFN-a2b for efﬁcacy in HCV therapy has generated conﬂicting
results that could be explained by the different dosing regimens,
(i.e. ﬁxed for PEG-IFN-a2a and weight-based for PEG-IFN-a2b),
and slightly different dosing of ribavirin. Furthermore, the HCV
subjects treatment history could affect the interpretation of results
in these trials since many HCV patients are co-infected with other
pathogens, including HIV, and these co-infections may well affect
the treatment outcome [11].
Though successful, IFN treatment often is accompanied with
undesirable systemic side effects, since virtually all cell types
express IFNAR. Common IFN-a induced side effects including
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fatigue, headache, pyrexia, myalgia, rigors and psychiatric
symptoms. Anemia, one of the common hematological abnormalities observed during treatment, is mainly caused by ribavirin,
while neutropenia and thrombocytopenia are a result of IFN-a
treatment [12]. Dose reduction or treatment discontinuation may
be necessary depending upon the severity of the symptoms. Due to
the potential systemic side effects, other IFNs molecules, including,
albumin-IFN-a, IFN-l (discussed in detail later in this review) and
consensus IFN-a, have been under study as potential candidates to
replace PEG-IFN-a. Albumin IFN-a2b is a product of a fusion gene
with the genes for IFN-a and human serum albumin. It is a
85.7 kDa molecule that retains the antiviral properties of IFN-a
with a 6-day half-life that is 2–4 fold longer than PEG-IFN-a [13].
The long half-life of albumin IFN-a allows a 2-week or even a
4-week dosing regimen which might limit the incidence of IFN-a
related side effects. Though a phase I/II trial showed promising
results, the results of a phase III trial raised concerns regarding the
safety of albumin IFN-a due to an increased incidence of not only
common IFN-a associated side effects but also pulmonary
complications as compared to the PEG-IFN-a2a treatment groups.
As a consequence, the application for FDA approval has since been
dropped [14,15].
Consensus IFN (CIFN) is a recombinant protein from a
consensus gene that consists of the most commonly observed
amino acids from several Type I IFN subtypes. CIFN has been shown
to have 10–100 times higher antiviral activity compared to
standard IFN-a, thus permitting a lower dosing regimen and
potentially limiting the incidence of IFN-a type side effects.
However, along with the stronger antiviral activities, CIFN still has
the disadvantages of recombinant IFN-a, i.e. rapid absorption,
short half-life and rapid elimination by the kidney. Thus, patients
require daily injection to maintain a SVR. An early phase III trial,
designed to evaluate the efﬁcacy of CIFN, showed that CIFN
monotherapy produced a higher rate of SVR compared to the
treatment with IFN-a2b. Furthermore, a treatment regimen
combining CIFN with ribavirin was shown to be effective in
treating PEG-IFN-a/ribavirin non-responders in a clinical trial [16].
Based on these promising phase III clinical trial results, CIFN
treatment is currently approved in the USA [11,17].
The combination of PEG-IFN/ribavirin has been the standard of
care for HCV infection for the past decade. However, the success of
treatment has been limited by suboptimal SVR rates in treatment
resistant patients, poor tolerability, and cumbersome treatment
regime. A huge effort has been made to optimize the HCV
treatment regimen in the hope to overcome the limitation of PEGIFN/ribavirin treatment. Extensive knowledge gained so far
regarding the HCV life cycle has stimulated the development of
direct antiviral agents (DAA) which target viral proteins to
interfere with their replication. There are four major groups of
DAAs, NS3/4A protease inhibitor (PIs), NS5B nucleoside polymerase inhibitors (NPIs), NS5B non-nucleoside polymerase inhibitors
(NNPIs) and NS5A inhibitors. In 2011, two PIs, telaprevir and
boceprevir were approved by FDA and when used in combination
with PEG-IFN/ribavirin treatment, signiﬁcantly increased the SVR
rate in treated patients. There are currently several promising
DAAs in clinical trials to investigate their efﬁcacy as monotherapy
or in conjunction with ribavirin or PEG-IFN/ribavirin. Though some
showed hepatotoxicity, most DAAs tested were well tolerated and
showed potent antiviral activity even in treatment resistant
patients. Most showed desirable SVR as a monotherapy and
achieved higher SVR when combined with PEG-IFN and ribavirin
[18,19]. The success in DAAs in clinical trials also stimulated the
development of IFN free treatment regimen by combining DAAs
with different functional proﬁles. IFN free treatment regimen is
beneﬁcial for patients with poor tolerance to IFN and/or who have
suffered from psychological disorders. Currently, there are clinical
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trials investigating the efﬁcacy of different DAA combinations as
anti-HCV therapy. The clinical results so far indicate that DAA
combination treatment potentially could have a shorter treatment
duration with better SVR [18]. Because of the undesirable side
effects and poor SVR of PEG-IFN/ribavirin regimen, the future of
HCV therapy will focus on developing IFN free treatment as the
standard of care. With the success in the clinical trials, one can
foresee the availability of such treatment in the near future.
However, the challenge in DAA combination treatment approaches
is the concern about selecting drug resistant strains of the virus.
Patients who are infected with such strains will have only one
feasible treatment PEG-IFN/ribavirin as interferon resistance has
not been observed. Thus, the traditional regimen with IFN-a will
remain a critical part in anti-HCV therapy.
2.4. IFN-a as a therapeutic agent for HBV infections
In addition to its use for the treatment of HCV, PEG-IFN-a2a
also has been used for treating chronic HBV infection. Even with
an effective vaccine, there are approximately 350–400 million
people infected with HBV, an infection rate that poses a serious
global health problem. Thought non-cytopathic, HBV is capable
of triggering immune responses and results in persistent hepatic
inﬂammation that ultimately leads to cirrhosis and HCC [20].
PEG-IFN-a2a was shown to effectively clear serum hepatitis B e
antigen (HBeAg), decrease the HCC rate and improve survival in
chronic HBV infected patients. Several studies also showed that
the PEG-IFN-a2a has a long lasting effect in maintaining
negative serum HBeAg after treatment when compared to
nucleoside analogues (NA), such as lamivudine (LMV), adefovir
(ADV), entecavir (ETV) and telbivudine (LdT) [21]. Though
successful, using PEG-IFN-a2a as a monotherapy was shown to
be less than ideal. In addition to the unpleasant side effects
induced by IFN-a as mentioned in this review, the percentage of
patients who achieved HBeAg seroconversion (from HBsAg to
hepatitis B surface antibody (anti-HBsAg)) is usually less than
35% with a relapse incidence of 5–10% [22]. Nevertheless, since
the IFN side effects can be managed by dose reduction or
termination of treatment, PEG-IFN-a2a still remains the
standard of care for chronic HBV infection according to World
Health Organization recommendations [23]. In order to improve
the treatment results, several groups have explored the option
of combing PEG-IFN-a2a with NA. In HBsAg positive chronic
HBV patients, the rates of undetectable serum HBV DNA and
seroconversion were higher in the group treated with combination therapy. In addition, the combination therapy also showed
superiority in maintaining long term HBeAg clearance and
seroconversion after the end of treatment period when
compared to PEG-IFN-a2a monotherapy [24–26]. During PEGIFN-a2a treatment, some patients lose serum HBeAg while
maintaining high levels of HBV DNA. These HBeAg negative
patients have been shown to have poor virological and
serological responses to PEG-IFN-a2a treatment and a higher
rate of virological relapse. Extended PEG-IFN-a2a treatment
beyond the traditional 48-week treatment regimen was shown
to improve the efﬁcacy among HBeAg negative patients. In
addition, sequential therapy with NA and PEG-IFN-a2a, monotherapy with NA or PEG-IFN-a2a followed by combination
therapy or mono therapy with NA or PEG-IFN-a2a, has been
shown to be a promising treatment for in HBsAg negative
patients as more than 50% pf HBsAg negative patients were able
to respond to treatment, and achieved SVR with signiﬁcant
decreased in serum HBV DNA [27,28]. Since these studies were
done with a small cohort, a clinical trial with signiﬁcant
numbers of recruits will be required to further validate the
efﬁcacy of sequential therapy in HBsAg negative patients.

2.5. IFN-b as a therapeutic agent for HCV infection
While IFN-b is most notably used as treatment in multiple
sclerosis, it also has been used in antiviral therapy since IFN-b has
been shown to have comparable antiviral activity to IFN-a. The
efﬁcacy of IFN-b as an alternative therapeutic option or in
combination with standard care for HCV infection has been
extensively investigated in Asia, including Japan, Korea and China
[29–31]. These studies not only proved the efﬁcacy of IFN-b as an
HCV therapy, but also showed promising results in overcoming the
treatment block in patients who had poor responses to IFN-a-2b/
ribavirin. Ishikawa et al. showed a higher percentage of patients
infected with HCV genotype 1, who were poor responders to IFNa-2b/ribavirin treatment, achieved SVR when treated with IFN-b
in the ﬁrst 2 weeks followed by IFN-a-2b/ribavirin compared to
IFN-a- 2b/ribavirin alone. Furthermore, a recent study showed a 2week lead-in IFN-b/ribavirin treatment followed by 46 weeks of
PEG-IFN-a/ribavirin treatment signiﬁcantly reduced the viral load
in patients carrying the IL-28 risk allele, a group that does not
respond to PEG-IFN-a/ribavirin treatment [32]. In addition,
treatment with IFN-b exhibited a low incidence of adverse effects
as compared to IFN-a. However, IFN-b treatment is rather
cumbersome as only a recombinant form of IFN-b is available
for treatment. This form of IFN-b has a shorter half-life and
requires a once daily or twice daily administration to reach a
desirable outcome.
2.6. Type I IFN as an adjuvant for antiviral therapy
In addition to a strong antiviral agent, Type I IFN also is a
powerful immunomodulation. Thus, multiple studies have utilized
Type I IFN as an adjuvant to enhance the efﬁcacy of a vaccine
regimen. A study investigating the efﬁcacy of IFN-a as an adjuvant
for the HBV vaccine in induction of an anti-HBeAg antibody
response in vaccine non-responders found a marginal increase in
the percentage of patients who developed antibody; 53% of IFN-a
treated subjects compared to 41% in the placebo group [33].
However, in a more recent study incorporating IFN-a in an HBV
vaccine regimen in healthy subjects, no difference in seroconversion rates and T cell responses between IFN-a and placebo groups
were observed [34].
Since a trend in an enhanced activation level in APCs was
observed, the authors speculate that an evaluation in the forms of
IFN-a, dosage and vaccine regimen that should be used in such
studies is needed in order to accurately assess the efﬁcacy of IFN-a
as an adjuvant.
3. Type II interferon: interferon-gamma (IFN-g)
3.1. IFN-gsignaling pathway
The active IFN-g molecule consists of two antiparallel and
intercalating polypeptides that fold into a twofold symmetry. The
dimer formation and folding are important to its biological
function and have been shown to be conserved among vertebrates
[35]. While virtually all cells express IFN-greceptors, the source of
IFN-g is restricted to certain cell types, namely natural killer (NK)
cells, T cells and NKT cells. The biological activity of IFN-g is
initiated upon binding to its receptor which consists of two ligandbinding IFN-gR1 chains whose expression level among cells is
consistently high and two signal-transducing IFN-gR2 chains
whose expression level is determined by the cell types and
activation status of the cells. IFN-g ﬁrst binds to IFN-gR1, and the
formation of IFN-g: IFN-gR1 complex facilitates its association
with IFN-g R2, that then initiates the downstream signaling events
[36]. The formation of this ligand receptor complex allows JAK1
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and JAK2, which constitutively bind IFN-gR1 and IFN-gR2
respectively through their N-terminal domains, to transactivate
each other. The activated JAKs then phosphorylate the tyrosine
residue on each IFN-gR1 chain to form the docking site for STAT1
which is then phosphorylated by the JAKs. The pSTAT1s form a
homodimer that translocates into the nucleus and initiates the
transcription of the target genes (Fig. 1) [37].
The JAK/STAT pathway is the primary signaling pathway
initiated by IFN-g stimulation. Similar to Type I IFNs, IFN-g also
can activate STAT1-independent pathways such as MAP kinase,
PI3K and the NF-kB signaling pathway as all have been shown to be
activated after IFN-g treatment [38]. In addition, it has been shown
that IFN-gcan also induce a non-canonical signaling pathway. In
this pathway, IFN-g, together with one of its receptor subunit
IFNGR1 and pSTAT1, translocate to the nucleus and induce gene
expression by binding to GAS elements in the promoter region of
IFN inducible genes [39].
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However, the results were not impressive as IFN-g did not improve
or only marginally improved the protective immune responses
against subsequent viral challenges. In addition to the possible use
in HIV treatment, IFN-g was also considered as a treatment option
for HCV and HBV. However, in a recent report, addition of IFN-g in
an HCV treatment regimen did not successfully suppress HCV
infection in patients who were non-responders to PEG-IFN/
ribavirin [42]. However, in this study, the timing of the IFN-g
treatment may be an issue, as it was added later in the treatment
regimen and it has been reported that virus elimination in the early
phase of treatment is closely associated with a better SVR rate.
Although the results of using IFN-g in HCV and HBV treatments
have been controversial, IFN-gmay have additional beneﬁts. A
study done by Wu et al. showed that HBsAg positive patients with
stage 2–4 hepatic ﬁbrosis achieved a signiﬁcantly improved
ﬁbrotic score after 9-months of IFN-gtreatment [43].
4. Type III interferon: interferon-lambda (IFN-l)

3.2. IFN-g antiviral activities
4.1. IFN-l signaling pathway
During virus infection, IFN-g can turn on the cellular antiviral
mechanism by inducing the expression of several antiviral
proteins. In addition to PKR, OAS and Mx GTPase mentioned in
the previous section, IFN-g can also trigger the expression dsRNAspeciﬁc adenosine deaminase (ADAR) which inhibits virus
replication by editing or causing mis-translation of viral proteins.
Similar to Type I IFNs, IFN-gcan induce apoptosis by up regulating
FasL to eliminate virus infected cells. Furthermore, IFN-g enhances
the expression of Type I IFN expression which further augments
the antiviral state of the cells. In addition to induction of antiviral
proteins, IFN-g also exercises its antiviral activity by modulating
both innate and adaptive immune responses. First, IFN-gcan
induce the expression of proinﬂammatory cytokines and chemokines by endothelial cells, epithelial cells and ﬁbroblasts to recruit
macrophages, neutrophils and T cells to the site of infection [40].
Importantly IFN-g plays a critical role in conveying antiviral
signals from the innate to the adaptive immune response in order
to fully activate host antiviral immunity. Upon receiving the IFN-g
signal, APCs increase expression of MHC class II and costimulatory
molecules which in turn facilitates CD4+ T cell activation and
initiation of the adaptive immune response against viral infection.
IFN-g also induces the expression of IL-12 by APCs. IL-12 not only
activates NK cells, a major antiviral cellular component of innate
immunity, but also drives CD4+ Th1 T cell development, a process
that is crucial in controlling viral infection.
3.3. IFN-g as a therapeutic agent for virus infection
Though a hallmark for Th1 response that results in strong
antiviral activity, IFN-gas an antiviral therapy for HIV has
generated disappointing results when tested clinically. Even with
its ability in enhancing CTL and NK cell activity, IFN-g failed to
decrease HIV viral loads in patients in a clinical trial designed to
evaluate the toxicity and efﬁcacy of IFN-g [40]. Thus, the focus of
IFN-g and HIV has shifted from using it as a monotherapy to
combining it with highly active anti-retroviral therapy (HAART).
HAART is a combination of two or more anti-retroviral drugs that
inhibits HIV replication and has dramatically reduced the HIVassociated morbidity and mortality. However, the occurrence of
opportunistic infections remains a serious problem in HARRT
treated HIV patients due to impaired T cell immunity. IFN-g has
been used with positive result as treatment for HIV-associated
opportunistic infections with or without HARRT to reconstitute the
immune response in HIV patients [41]. With the importance of IFNg in the host Th1 response, several groups incorporated IFN-g into
DNA vaccine regimes as an adjuvant in HIV animal models [40].

Human Type III IFNs or IFN-ls, including IFN-l1, IFN-l2 and
IFN-l3 (or IL-29, IL-28A and IL-28B respectively), were identiﬁed
by two independent groups in 2003. Though structurally related to
IL-10-related cytokines, IFN-l can induce antiviral activity in a
variety of target cells that express the IFN-l receptor [44]. Thus,
they have been functionally classiﬁed as a new type of IFN. The IFNl proteins bind and signal through a receptor complex composed
of the IL-10R2 chain (also an essential part of the receptor
complexes for IL-10, IL-22, and IL-26), and the IFN-lR1 chain (also
known as IL-28RA) which is utilized only by IFN-l. Although IFN-l
can be expressed by virtually all cell types that can be infected with
virus, the IFN-lR1 subunit is constitutively expressed by limited
cell types, primarily cells of epithelial origin. IFN-lR1 was shown
to also be expressed on some blood immune cells including B cells,
T cells, DCs and macrophages. However, these cells expressed a
short IFN-l receptor splice variant (sIFN-lR1/sIL-28R1) which
results in a weaker signaling strength when stimulated with IFN-l
[45]. In contrast, ﬁbroblasts, endothelial cells and most leukocytes
do not express the full length IFN-lR1 chain; therefore, they do not
response to IFN-l stimulation. IFN-l ﬁrst binds to the IFN-lR1
chain, resulting in a conformation change that facilitates the
recruitment of IL-10R2. Formation of the IFN-l and IFN-l receptor
complex leads to JAK activation, followed by tyrosine phosphorylation of the intracellular domain of the IFN-lR1 chain, resulting
in STAT1 and STAT2 activation (Fig. 1). Signaling through either
IFN-l or IFN-a receptor complexes results in the activation of the
same JAK–STAT signal transduction cascade; though the signaling
strength induced by IFN-l is comparatively weaker [46].
4.2. Antiviral activities
Similar to Type I IFN, IFN-l has the ability to induce antiviral
activity in target cells. It has been established that IFN-l can inhibit
HBV replication in different murine hepatocyte cell lines, as well as
the replication of a subgenomic and full length HCV replicon in a
human hepatoma cell line [47,48]. Recent reports also demonstrated that IFN-l inhibits HIV-1 replication in macrophages and
primary T cells [49,50]. Virus inhibition by IFN-l was also shown in
vivo when locally delivered recombinant IFN-l inhibited HHV-1,
HHV-2 and IAV replication in the vagina and lungs [51]. Similar to
Type I and II IFNs, IFN-l also can induce the expression of the
antiviral hallmark proteins, OAS and Mx protein [52]. In addition to
inhibiting virus replication, IFN-l can limit prolonged virus
infection by up-regulating the expression levels of MHC class I
proteins on the cell surface, which in turns facilitates the
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recognition and destruction of virus-infected cells by the innate
immune system, and by inducing apoptosis of the virus infected
cells [53].
4.3. PEG-IFN-l as a therapeutic agent for HCV infection
Due to the rapid genetic changes that render HCV resistant to
drugs targeting virus replication and assembly, IFN-a treatment
remains an effective therapy for HCV infection, despite the array of
systemic side effects. However, as the restricted tissue expression
of the IFN-lR1 chain ensures a localized reaction, the antiviral
activity of IFN-l makes it a much safer and less toxic choice as a
therapeutic agent for virus infection. As the preclinical studies
showed that PEG-IFN-l inhibited HCV replication in human
hepatocytes without hematological cytotoxicity, a phase IA dose
escalation study in healthy volunteers was conducted in 2007
[54,55]. Subjects received a single dose of PEG-IFN-l injected
subcutaneously. All testing dosages (0.5, 1.5, 5 and 7.5 mg/kg) were
well tolerated, and no IFN induced side effects were observed in the
subjects. However, a few volunteers in 7.5 mg/kg group developed
signiﬁcant elevated transaminase which was considered a doselimiting toxicity and could be reversed by lowering the IFN dosage.
A subsequent phase IB study was conducted to evaluate the
efﬁcacy and cytotoxicity of IFN-l in HCV infected patients,
including both treatment-naı̈ve patients and patients who
relapsed after previous IFN-a treatment. Recruited patients
received PEG-IFN-l with or without ribavirin weekly or bi-weekly
at the dose range from 0.5 to 3 mg/kg for 4 weeks.
During the trial, six of the patients had elevated transaminase
which resolved after stopping treatment. Overall, there was a
signiﬁcant decrease in the incidence of IFN-a type side effects, and
unlike PEG-IFN-a, PEG-IFN-l treatment did not exhibit signiﬁcant
hematological toxicity. Most importantly, patients receiving
1.5 mg/kg/week exhibited at least two logs reduction in viral
load; four logs when combined with ribavirin treatment.
Unexpectedly, two of the patients who previously were treated
with IFN-a developed antibodies cross-reactive to IFN-l, an
observation that implies the efﬁcacy of IFN-l treatment may
be limited in some patients previously treated with IFN-a.
Three independent genome-wide association studies (GWASs)
have identiﬁed SNPs in the IL28B gene as being associated with the
outcome to treatment with PEG- IFN-a/ribavirin in HCV patients
[56]. A 12-week phase IIA clinical study was conducted that
compared the safety and antiviral activity of four ﬁxed doses of
PEG-IFN-l to PEG-IFN-a in treatment-naı̈ve HCV patients. The
percentage of patients with undetectable virus was signiﬁcantly
higher in those with the favorable genotype (86%) compared to
those carrying the risk allele (50%). These results suggest that
the efﬁcacy of treatment with PEG-IFN-l will differ according to
IL28B genotype [54]. The most recent phase IIB trial was designed
to assess the safety, efﬁcacy, and pharmacokinetics of ﬁxed dose
PEG-IFN-l vs. PEG-IFN-a in 526 treatment-naı̈ve patients infected
with HCV genotypes 1, 2, 3 and 4. Patients received PEG-IFN-l
240 mg, PEG-IFN-l 180 mg, PEG-IFN-l 120 mg or PEG-IFN-a
180 mg weekly, all in combination with daily ribavirin. The
treatment period is 48 weeks for HCV genotype 1 and 4 patients
who exhibited a poor response to PEG-IFN-a and ribavirin
treatment and 24 weeks for HCV genotype 2 and 3 patients.
Treatment with PEG-IFN-l and ribavirin achieved higher rates of
rapid virologic response (RVR) and a complete early virologic
response (cEVR) regardless of the HCV genotypes as compared to
the treatment with PEG-IFN-a/ribavirin. Furthermore, there were
fewer incidences of IFN-a type side effects, as well as fewer dose
reductions for anemia in the PEG-IFN-l treatment group up to 12
weeks. However, the incidence of serious adverse events was
similar across treatment groups up to week 12 [57]. The results of

the phase III trial thus far demonstrate the potential for using IFN-l
as therapy in HCV infection. Careful titration of dosage should
result in a treatment regimen that would inhibit viral replication
but at the same time reduce adverse effects. Based on the success in
the use of IFN-l for HCV therapy clinical trials, one can foresee the
possible incorporation of IFN-l in the treatment of other viral
infections.
5. IFNs as therapeutic agents in other diseases
In addition to antiviral therapy, IFNs also have been used as
therapeutic agents in cancer and autoimmune diseases. Due to its
antiproliferative, antiangiogenesis and immunomodulatory
effects, IFN-a has been included in several cancer treatment
regimens as an adjuvant. In melanoma, high-dose IFN-a2b
regimen (HDI, both recombinant and pegylated forms) has been
approved for use as part of the treatment as multiple metaanalyses have shown that HDI signiﬁcantly increases disease-free
survival and overall survival in high-risk cutaneous melanoma
[58,59]. IFN-a also has been evaluated in multiple clinical trials as
part of therapy regimen for renal cell carcinoma [60–63]. In these
trails, patients achieved longer progression free survival when
treated with low dose IFN-a in combination with a variety of
chemotherapeutic drugs. Before the discovery of tyrosine kinase
inhibitor, Imatinib, IFN-a was the choice of treatment for chronic
myeloid leukemia (CML). While Imatinib still remains the frontline
treatment for CML, several groups set out to improve the efﬁcacy of
Imatinib by combining PEG-IFN-a2a or PEG-IFN-a2b into the
treatment regimen. The results of these studies showed that the
addition of PEG-IFN signiﬁcantly reduced the number of leukemia
cells in treated patients [64–66]. In 1993, IFN-b was ﬁrst approved
for multiple sclerosis (MS) treatment in the USA. Currently, there
are several FDA approved IFN-b products available (Table 1). While
ﬂu-like symptoms are commonly observed in treated patients, IFNb treatment for MS is considered safe and effective. Although the
exact mechanism of how IFN-b inhibits the progression of MS is
unknown, its anti-inﬂammatory effects and its abilities to induces
the generation of regulatory T cells, prevent leukocytes from
crossing the blood brain barrier and promote apoptosis in
autoreactive T cells make IFN-b an attractive treatment option
for MS [67,68]. Compared to Type I IFNs, IFN-gdoes not get utilized
as broadly in the clinic. However, IFN-ghas been shown to be
effective in controlling sever idiopathic atopic dermatitis by
decreasing blood eosinophil count, and inhibiting IgE synthesis
and T-cell proliferation [69]. IFN-galso has been used in patients
with chronic granulomatous disease, a disorder with a defect in the
enzyme complex responsible for phagocyte superoxide generation.
However, the use of IFN-gin these patients is to prevent the
reoccurrence of infections, not as a treatment for the underlying
genetic disease [70].
6. Conclusion
Some viruses, such as HCV, HBV and HIV, are able to evade host
immune responses and cause a state of chronic infection in the
host. In these infections, reducing and eliminating viral replication
requires therapeutic intervention. Due to the high incidence of
genomic mutation, viruses are able to adapt and develop resistance
to drugs that target essential viral proteins. Thus, a treatment that
could restore and strengthen the host antiviral immune response
becomes crucial in controlling virus infection. The strong antiviral
activity of IFN proteins and their ability to modulate the immune
response make the IFNs the perfect candidates to use in antiviral
therapy. However, the immune system is an extremely complicated machine that requires delicate and subtle manipulation to
maintain the balance between health and disease. IFNs are such
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powerful cytokines that using them as treatments for diseases may
well offset immune homeostasis by hyperactivation of the host
response. In addition, as a wide range of cell types are responsive to
stimulation by IFNs, the consequences of IFN use stretch beyond
the immune system. Therefore, the clinical use of IFNs to
successfully suppresses virus replication and contain a spreading
infection will require constant monitoring of patients for
potentially detrimental side effects that go beyond enhancing
the host anti-viral response.
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